Rafferty Asset Management
DAWN

Rafferty Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Rafferty Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Sell
59,207
-97,803
-62% -$1.38M 0.01% 711
2025
Q4 		$1.46M Buy
157,010
+29,430
+23% +$246K 0.01% 720
2025
Q3 		$899K Buy
127,580
+28,889
+29% +$199K ﹤0.01% 816
2025
Q2 		$641K Sell
98,691
-20,469
-17% -$141K ﹤0.01% 838
2025
Q1 		$945K Sell
119,160
-40,248
-25% -$434K ﹤0.01% 754
2024
Q4 		$2.02M Buy
159,408
+22,975
+17% +$320K 0.01% 646
2024
Q3 		$1.9M Sell
136,433
-13,222
-9% -$189K 0.01% 650
2024
Q2 		$2.06M Sell
149,655
-43,569
-23% -$637K 0.01% 630
2024
Q1 		$3.19M Sell
193,224
-43,123
-18% -$645K 0.01% 562
2023
Q4 		$3.45M Sell
236,347
-737
-0.3% -$8.94K 0.01% 521
2023
Q3 		$2.91M Sell
237,084
-53,924
-19% -$703K 0.02% 504
2023
Q2 		$3.47M Buy
291,008
+99,563
+52% +$1.3M 0.02% 495
2023
Q1 		$2.56M Sell
191,445
-14,001
-7% -$273K 0.02% 538
2022
Q4 		$4.42M Buy
205,446
+60,812
+42% +$1.25M 0.04% 402
2022
Q3 		$2.9M Buy
+144,634
New +$3.08M 0.03% 425

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Rafferty Asset Management's DAWN Position: Q1 2026 in Review

Rafferty Asset Management reduced its Day One Biopharmaceuticals (DAWN) stake by 62% in Q1 2026, selling an estimated $1.38M and leaving 59,207 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #711.

Rafferty Asset Management first reported a position in DAWN in Q3 2022 and has held it in 15 quarters since. The position peaked at $4.42M in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Rafferty Asset Management held 59,207 shares of Day One Biopharmaceuticals worth $1.27M as of Q1 2026.
  • Rafferty Asset Management sold 97,803 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.38M.
  • Day One Biopharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #711 holding.
  • Rafferty Asset Management first reported a position in Day One Biopharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Rafferty Asset Management's Day One Biopharmaceuticals position peaked at $4.42M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.